Leukemia & Lymphoma
Volume 62, 2021 - Issue 9
Open access
3,036
Views
5
CrossRef citations to date
0
Altmetric
Original Articles
Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma*
Wyndham H. Wilsona Lymphoma Therapeutics Section, National Cancer Institute, Bethesda, MD, USACorrespondence[email protected]
View further author information
, View further author information
Tycel Phillipsb Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USAView further author information
, Leslie Popplewellc Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USAView further author information
, Sven de Vosd Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USAView further author information
, Saurabh Chhabrae Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USAView further author information
, Amy S. Kimballf University of Maryland School of Medicine, Baltimore, MD, USAView further author information
, Darrin Beaupreg Early Development and Immunotherapy, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USAView further author information
, Da Wei Huanga Lymphoma Therapeutics Section, National Cancer Institute, Bethesda, MD, USAView further author information
, George Wrighta Lymphoma Therapeutics Section, National Cancer Institute, Bethesda, MD, USAView further author information
, Kevin Kweih Department of Translational Medicine, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USAView further author information
, Jerry Pingi Department of Statistics, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USAView further author information
, Jutta K. Neuenburgj Department of Oncology, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USAView further author information
& Louis M. Staudtk Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD, USAView further author information
show all
Pages 2094-2106
|
Received 09 Sep 2020, Accepted 06 Mar 2021, Published online: 15 Apr 2021
Reprints and Permissions
This is an open access article distributed under the terms of the Creative Commons CC BY license, which permits unrestricted use, distribution, reproduction in any medium, provided the original work is properly cited.
You are not required to obtain permission to reuse this article in part or whole.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.